APA (7th ed.) Citation

Wang, H., Liu, Y., Zhu, C., Yan, F., Wang, M., Chen, X., . . . Dou, L. (2020). Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. Journal of experimental & clinical cancer research, 39(1), 278-19. https://doi.org/10.1186/s13046-020-01792-8

Chicago Style (17th ed.) Citation

Wang, Hao, et al. "Chidamide Increases the Sensitivity of Refractory or Relapsed Acute Myeloid Leukemia Cells to Anthracyclines via Regulation of the HDAC3 -AKT-P21-CDK2 Signaling Pathway." Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 278-19. https://doi.org/10.1186/s13046-020-01792-8.

MLA (9th ed.) Citation

Wang, Hao, et al. "Chidamide Increases the Sensitivity of Refractory or Relapsed Acute Myeloid Leukemia Cells to Anthracyclines via Regulation of the HDAC3 -AKT-P21-CDK2 Signaling Pathway." Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, 2020, pp. 278-19, https://doi.org/10.1186/s13046-020-01792-8.